|Articles|September 14, 2005

Ruptured Tendon From Prednisone Therapy

The unusual muscle definition in this 57-year-old man was noted during a routine physical examination. The patient had myasthenia gravis, for which he previously had been treated with prednisone.

The unusual muscle definition in this 57-year-old man was noted during a routine physical examination. The patient had myasthenia gravis, for which he previously had been treated with prednisone. A possible complication with use of this agent is spontaneous rupture of the biceps tendon, which had occurred bilaterally in this man. Fortunately, he suffered no adverse effects from these ruptures. This photo was sent by Dr David L. Kaplan of Overland Park, Kan.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Latest CME

Multimedia

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

Ruptured Tendon From Prednisone Therapy

Related Content

GLP-1 RA Use Accelerates Among US Children Aged 8 to 11 Years With Obesity

FDA Approves Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine for 2026-27 Season

Diagnosing PMOS in Adolescents: Criteria, Ultrasound Limits, and Red Flags

Independent Review Supports Respiratory Virus Immunizations for 2026-27 Season

Primary Care Lens: Sepsis Prevention and Recognition in Primary Care

Latest CME

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Kentucky

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

2026 Carolina Neuromuscular Disease Summit

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Nevada Oncology Society

Kansas Society of Clinical Oncology

EyeCon 2026

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Rhode Island Oncology Society

27th Annual International Lung Cancer Congress®

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

The Optometry Meeting in Anaheim

North Carolina Oncology Association

Jersey City Psychiatry

Join Us at The Pathology Meeting in Las Vegas

Join Us at The Pathology Meeting in Las Vegas

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Montana/Wyoming

Join Us at The Ophthalmology Meeting This October in New Orleans

Tennessee Oncology Practice Society

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

Washington State Medical Oncology Society

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Show Me the Data™: HER2-Mutant NSCLC in Transition — Translating Evidence to Practice

Missouri Oncology Society

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

IgAN Case Files: Real Conversations, Evolving Evidence

New Mexico Society of Clinical Oncology

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Kentucky

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

ISGIO 2025: Advanced-Stage Colorectal Cancer

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

ISGIO 2025: Hepatobiliary Cancers

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies

ISGIO 2025: Early-Stage Colorectal Cancer

ISGIO 2025: Esophageal and Gastric Cancer

4th Annual International Congress on Pediatric Oncology

Community Practice Connections™ Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, and Beyond!

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Optimizing Multidisciplinary Care in TGCT